X

Auro Laboratories Ltd Stock Analysis

Small Cap
Evaluated by 350 users | BSE: 530233 | NSE: |
Pharmaceuticals & Drugs
Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah. Company’s manufacturing facility is located at Tarapur...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 5.81%7.36%9.26%8.38%7.99%7.96%6.47%19.6%18.47%15.37%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 20.425.444.333.732.727.935.540.846.843.8
Y-o-Y Gr. Rt.-24.8%74.1%-23.8%-3.2%-14.5%27.1%15%14.8%-6.5%
Adjusted EPS (Rs.) 0.340.751.231.291.071.030.785.166.095.54
Y-o-Y Gr. Rt.-120.6%64%4.9%-17.1%-3.7%-24.3%561.5%18%-9%
Book Value per Share (Rs.) 8.498.9110.1411.0712.3613.7815.120.8227.9434.49
Adjusted Net Profit 0.20.50.80.80.70.60.53.23.83.5
Net Op. Cash Flow (Rs. Cr.) -0.52.51.54.5-0.87.95.94.86.99.2
Debt to Cash Flow from Ops -27.576.3811.53.3-21.011.61.691.931.180.34
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Auro Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 8.9%6.1%7.3%-6.5%
Adjusted EPS 36.4%38.9%92.2%-9%
Book Value per Share 16.922.831.723.4
Share Price 38.4% 32.6% 2.2% 155.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 4.098.6112.9112.29.157.895.4128.7224.9617.73
Operating Profit Margin (%) 6.459.467.49.2910.0412.4815.5914.9414.32
Net Profit Margin (%) 1.041.841.732.392.052.31.377.888.17.88
Debt to Equity 2.472.872.652.142.131.471.050.710.460.15
Working Capital Days 208205131169173188124119112112
Cash Conversion Cycle 1201025575939139293739
Entity Percentage Holding
Promoters 51.92%
Institutions 0.01%
Non-Institutions 48.07%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Auro Laboratories Ltd's performance infers:

Auro Laboratories Ltd earnings have grown by 38.9%, whereas share price has appreciated 32.6% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Auro Laboratories Ltd share prices over the last 10 years. Here is what we found out:

Auro Laboratories Ltd share price has appreciated 28.7% annually over the past ten years.

Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.

Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on

Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.

Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.

Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others.   Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.

Products

APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.

Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.

Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and  5-Bromo Phthalide

Milestones

1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.

1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).

2004-Company received ISO 9001:2000 certification.

2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).

2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.

Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback